Synchroneuron
VerifiedBiopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$80—120m (Dealroom.co estimates Jul 2014.)
Duxbury Massachusetts (HQ)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | $0.0 | round | |
$20.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
Recent News about Synchroneuron
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.